As I listened to the amazing sessions at this year's Summit, the rage from 2016 was still there, and rightly so, but there was also so much love, inclusivity and power. Whether you like the term 'patients' or not - we debated it at the Summit - this event was full of patients taking back their power. I was proud to be part of it and continue to be proud that T1International is making such a huge global impact as a small, pharma-free charity. Read more
Over the past few months, many insulin manufacturers and other entities have announced that they will be lowering the price of insulin in the United States. So, why is insulin still so expensive?
We recently released our Policy Playbook that goes through all of the details and gives advocates the information to push for change locally and nationally. Why insulin is so expensive can be boiled down to three main points. Read more
On March 1, Eli Lilly announced it would reduce the list prices of some of its insulins, including the generic Lispro, the same product as the name-brand Humalog. At a recent congressional hearing with the CEOs of insulin manufacturers and pharmacy benefit managers, David Ricks, Eli Lilly’s CEO, again celebrated that $25 insulin lispro was available to patients as of May 1. People with diabetes have worked tirelessly to reduce insulin costs for decades. So why aren’t we universally celebrating this announcement of lower prices? Because it is now the end of May, and I - and many others in my community - still haven’t been able to get the promised $25 insulin.
Advocates recently gathered in Washington, DC to attend the Senate HELP Committee Hearing entitled: The Need to Make Insulin Affordable for All Americans. The hearing, led by Chairman Senator Bernie Sanders, is the culmination of a decade of advocacy efforts by the #insulin4all community who have demanded public accountability for the global insulin price crisis. Read more
Following years of advocacy on affordable insulin for T1International, today Eli Lilly announced that vials of generic insulin Lispro will be available to all US customers for $25 effective May 1, 2023. Some other Eli Lilly insulins will also be made more affordable by the end of the year. Current list prices for insulin can be over $300 per vial. Read more
Patents are intended to provide an exclusive right for a novel invention. By granting a protected property right to an inventor, patents are intended to spur innovation because the patent holder can make significant money for a limited time in exchange for publishing and disclosing the invention. However, the patent system has been exploited by Big Pharma to keep charging high prices on old insulins, or only changing their products in small ways. Read more
Research conducted by T1International finds that people living with diabetes are experiencing diabetes burnout at a very high rate, with a significant impact on their health and wellbeing. Read more
With many successes and key moments to reflect on, it is nearly impossible to recap all in a single post. Instead, you can hear favorite moments directly from the 14 members of the T1International team! Read more
Voices from around the world were part of the T1International Rally and March outside Eli Lilly on October 24th, where #insulin4all activists demanded Eli Lilly immediately lower the list price of insulin and defended the lives of those who are rationing insulin just to survive. Read more
A recent study of 2021 National Health Interview Survey data demonstrates what #insulin4all advocates have been saying for years: too many people are dangerously rationing insulin due to cost. While insulin costs around $6 to manufacture, three companies dominate more than 90% of the insulin market and charge around $300 for a single vial of insulin. Read more